On 26 May 2008, NeuroSearch increased its share capital with the issue of
300,000 new shares of DKK 20 nominal value each at a price of DKK 280 each to
finance a milestone related to the initiation of a Phase III study with ACR16
in Huntington's disease.
Pursuant to section 6 of Executive Order no. 1172 of 9 October 2007 on Issuers'
Disclosure Obligations, it is hereby announced that at the end of May 2008, the
total nominal value of NeuroSearch A/S' share capital is DKK 314,834,640, which
is made up of 15,741,732 shares with a nominal value of DKK 20 each, and
corresponding to 314,834,640 votes.
Thomas Hofman-Bang
Chairman of the Board
Contact persons:
Flemming Pedersen, CEO, telephone: +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications, telephone: +45 4017 5103
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the
OMX Nordic Exchange Copenhagen A/S. The core business covers the development of
novel drugs, based on a broad and well-established drug discovery platform
focusing on ion channels and CNS disorders. A substantial part of NeuroSearch's
activities are partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with among others Abbott and Astellas. The drug
pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in
Huntington's disease (Phase III), tesofensine in obesity (Phase III in
preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in
partnership with GSK, ABT-894 in ADHD (Phase II) and pain (Phase II) in
partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with
Astellas, ACR325 in bipolar disorder (Phase I), ABT-107 as well as ABT-560 for
the treatment of various CNS disorders - both (Phase I) in collaboration with
Abbott, NSD-644 in pain (Phase I) in partnership with GSK, ACR343 in
Parkinson's disease (Phase I) and NSD-788 in anxiety/depression (Phase I). In
addition, NeuroSearch has a broad portfolio of preclinical drug candidates and
holds equity interests in several biotech companies.
